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Abstract: A five-years long study aiming to describe the basic genetic epidemiology of the dystrophinopathies
in Costa Rica recruited 31 patients with clinical symptoms of DMD/BMD at the National Children’s Hospital
(HNN). This center is the obligate reference hospital of the national health system for genetic diseases, howev-
er, the geographic origin of the patients, a low percentage of deletions and a high proportion of de novo muta-
tions found among them indicate that a significant ascertainment bias impedes a substantial scientific approach
to confront and alleviate the problems posed by these severe diseases in Costa Rica. Rev. Biol. Trop. 52(3): 485-
490. Epub 2004 Dic 15.
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The dystrophinopathies are a group of
hereditary diseases mainly characterized by
skeletal muscle dysfunction. They are caused
by mutations at the X-linked dystrophin gene
(MIM 300377) that maps to Xp21 (Murray et
al. 1982). The severity of these diseases varies
from myalgia and cramps to lethality at prere-
productive ages resulting from a progressive
muscle wasting that eventually impairs venti-
lation, compromising the heart and thus lead-
ing in most cases to death from cardiac failure
(Emery 1993, and for a more updated review
see OMIM).
The most frequent and devastating of
them is Duchenne muscular dystrophy (DMD,
MIM 31022) (Duchenne 1861, 1868) with an
estimated incidence of 1:3 500 male births,
whereas the estimated incidence of its allelic
form Becker-Kiener muscular dystrophy
(BMD, MIM 300376) (Becker and Kiener
1955) is 1:18 500 male births. Together they
account for 40% of the muscular dystrophies
(Emery 1991). Both diseases follow an X-linked
recessive pattern of inheritance (Becker 1953,
OMIM 2004), thus, the great majority of
patients are males. However, severity and
course of symptoms are different in both enti-
ties: the outcome of DMD is fatal, patients are
chair-bound by the age eleven, death occurs
shortly after the beginning of the second
decade of life, while BMD, although physical-
ly handicapping, is milder, allowing some
patients even to reproduce (for more details see
Emery 1991).
One of the first genes discovered by posi-
tional cloning was the dystrophin locus
(Murray et al. 1982, Koenig et al. 1987). The
gene is segmented in at least 79 exons and cov-
ering 2.4 Mb, is the largest human gene
known. This knowledge promptly opened the
possibility to further study its fine structure
and its expression patterns, as well as the
nature of the disease-causing mutations. The
gene shows a huge expression plasticity, which
gives an idea on the many physiological roles
it could play. Its full mature mRNA, in muscle
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for example, is 14 kb, less than 1% of the
whole DNA gene extension. In addition, sever-
al full and partial transcripts are specifically
expressed in different tissues because several
tissue-specific promoters regulate the gene and
because some of its transcripts are differential-
ly spliced. Further details on these topics can
be found in Ahn and Kunkel (1993), Tinsley et
al. (1993) and OMIM.
RELATION BETWEEN 
MUTATION AND DISEASE
Deletion is the most common type of
mutation causing dystrophinopathies. Almost
two thirds of the patients present deletions
ranging from small parts of the gene, segments
of one exon, to large amounts involving tens of
exons (Emery 1993). However, severity is not
associated with the size of the deleted frag-
ment, but with the preservation of the reading
frame of the gene. Both, large and small dele-
tions altering the sense of the message lead to
DMD, whereas deletions, which, independent-
ly of their size, allow an in-frame splicing of
the sequence produce BMD (Gillard et al.
1989, Koenig et al. 1989, Covone et al. 1991).
Five to ten percent of deleterious mutations
affecting the gene are duplications, and the rest
are small insertions, inversions and point
mutations (Hu et al. 1990, Roberts et al. 1992,
Prior et al. 1995, Baxter et al. 1997).
The cloning of the gene allowed the devel-
opment of multiplex PCR protocols that make
possible the fast and easy detection of deletions
(Chamberlain et al. 1988). Further development
of the technique increased its detection sensibil-
ity to more than 98% (Beggs et al. 1990).
THE SITUATION IN COSTA RICA
The theoretical knowledge on the molecu-
lar causes of dystrophinopathies and the tech-
nical improvements described, together with
the fact that Costa Rica has a health profile
similar to those of developed countries prod-
uct of governmental sanitary polices and of a
universal health system (Mohs 1982) indicated
that an epidemiological genetic approach to
these diseases could be attempted in the coun-
try. Therefore, a study was conducted
between1998 and 2002 aiming to define the
epidemiological profile of these diseases and
the frequency of deletions among dystrophino-
pathic patients. The project was a collabora-
tion between the University of Costa Rica
(Section of Human Genetics, Institute for
Health Research –INISA- and School of
Medicine) and the Service of Genetics and
Metabolism of the National Children’s
Hospital (HNN) of the Caja Costarricense de
Seguro Social (CCSS).
During these 5 years, 31 cases with clini-
cal symptoms of dystrophinopathies, 2 BMD
and 29 DMD, were detected among the
patients of the HNN. The Service should be
the best place where to find patients for stud-
ies like this since it is the only Genetics
Service of the national health system, thus it
should recruit most of the cases of the country.
However, only one patient from the Province
of Limon did not originate from the Central
Valley of the Land (San José, Alajuela,
Heredia and Cartago).
Peripheral blood was obtained from these
patients and, when available, from their close
female relatives (mother, sisters, maternal
aunts, grandmothers). DNAs were extracted
and multiplex PCRs (Chamberlain et al. 1988,
1990, Beggs et al. 1990) were performed to
screen for deletions at the dystrophin gene
with the modifications described elsewhere
(Sancho et al. 2001). For some cases where
deletions were observed, DNAs from close
female relatives at risk of being carriers were
tested by fluorescent dosage analysis
(Azofeifa and Sancho-Fernández 2001). In
addition, five dinucleotide microsatellites
were used to construct haplotypes and esti-
mate this risk for the females in a family where
the index patient does not have detectable
deletions (Chavarría et al. 2002).
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THE SCREENING FOR DELETIONS
Twelve of the 31 patients clinically diag-
nosed as dystrophinopatics (39%), one of them
a BMD, showed deletions (Fig. 1). This is a
remarkable low number since two thirds
(expected 21) is a constant figure found in dif-
ferent studies around the world (Emery 1993)
and which is in agreement with theoretical pre-
dictions based on equilibrium between selec-
tion and mutation rates (Haldane 1932, 1935).
This result could be explained by a least two
reasons, a biased and small sample size and/or
wrong differential diagnosis of some patients
since other diseases resemble the symptoms of
DMD and BMD (Emery 2002).
The size of the deletions found in the
Costa Rican patients ranged from at least 1 to
23 exons and their distribution within the gene
was as expected since they cluster around two
regions known to be deletion prone, i.e.
between exons 3 and 19, and between exons 44
and 52 (Fig. 1), according to different studies
(Speer and Oexle 1999). However, an excess
36% (20% expected) involves deletions within
the first region, and, consequently, a deficient
63% (80% expected) is found within the sec-
ond region (Speer and Oexle 1999). This dif-
ference is probably due to the small number of
cases with deletions found in this study.
THE DETERMINATION OF CARRIER
STATUS OF FEMALE RELATIVES
The strategy to determine, or to estimate,
the carrier status of at-risk female relatives of
patients affected with a dystrophinopathy
Fig. 1. Distribution and size of the deletions detected between 1998 and 2002 along the dystrophin gene in DMD/BMD
patients from Costa Rica. The length of the horizontal lines represents the extent (exons) of each deletion and the numbers
indicate the flanking deleted exons. Dys 31 is a BMD-patient with a deletion covering at least 8 exons (45 to 52), all other
patients are affected with DMD. Dys 11, Dys 16, Dys 44 and Dys 100 have deletions of single exons, whereas Dys 80 car-
ries the longest deletion, 23 exons, found out in Costa Rican patients.
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depends on the familial history and/or the type
of mutation causing the disease. The presence
of several patients in the family allow, in some
cases, the identification of obligate carriers by
segregation analyses. If deletions are found, a
direct approach, fluorescence in situ hybridiza-
tion (FISH), using as probes those segments
deleted in the index patient, can detect on a chro-
mosomal preparation the mutation. Another way
to test if a female is a carrier is by fluorescence
dosage analysis. If she carries the deletion affect-
ing the index patient, she will be hemizygous for
the deleted segment of the gene. Combining
multiplex PCR, using primers marked with a flu-
orescent dye, and capillary electrophoresis, the
height or the area of the peak produced by the
signal of the fragment should be proportional to
the quantity of molecules serving as templates,
at the PCR exponential phase, for the amplifica-
tion, i.e. to the dosage of the gene segment
amplified. Thus, relative ratios of the area of
each fragment, calculated over all the segments
simultaneously amplified, should disclose if the
putative carrier has an imbalance at the deleted
segment when compared with a mean value
obtained from normal females. Using this
approach, 15 females maternally related to 6
patients (DYS 05, DYS 11, DYS 31, DYS 44, DYS
80, and DYS 94, see Fig.1) without familial his-
tory of DMD/BMD were tested (Azofeifa and
Sancho-Fernández 2001). All of the ratios
showed mean values similar to those of the con-
trol group indicating first, that they do not carry
any deletion, and second, that the deletions doc-
umented in all 6 index-patients were originated
by de novo mutations.
On the other hand, if the index patient has
no identifiable deletions, an indirect method
must be used to estimate risk figures. The most
useful is based on the determination of haplo-
types with markers around and within the dys-
trophin gene and a concomitant segregation
analysis among all possible maternal family
members, including other males (brothers,
cousins). Once the haplotype of the index
patient is determined its segregation pattern
will indicate if the mutation was a de novo
event or if it is actually segregating in the
family through more female relatives.
Nineteen members, 11 females and 8 males, of
one family not recruited during the collabora-
tive INISA-HNN project, where the index
patient has no deletions were screened in this
way (Chavarría et al. 2001). The haplotype of
the patient is also carried by two of his first
cousins, both healthy adults. This haplotype
could be traced back to their maternal grand-
mother. Since there are no familial antecedents
of DMD, this indicates that the mutation
occurred de novo either in the germ line of the
grandmother or of the mother of the patient.
Anyway, as the patient has no sisters, only two
brothers who inherited the X chromosome of
their maternal grandfather, the mutation will
no longer segregate in this family.
Summarizing, all 7 index-patients,
belonging to families without previous history
of dystrophinopathies, carry mutations product
of de novo mutations. It is important to outline
here that among the patients without deletions
7 had familial history letting us to suppose that
their mothers are carriers. For several reasons
no data are available on this subject for the
other 18 patients recruited and their families.
If only the 7 cases analyzed are consid-
ered, there should be only one third expected
to be the product of de novo mutations, in this
case 2.33 patients (Emery 1993). A very plau-
sible explanation to this finding could be that
familial cases are underrepresented in this
study. Among the 31 total cases studied only 9
had familial antecedents of dystrophinopathy.
Given the fatal course of DMD and despite
treatments offered to the patients, a natural
attitude of parents would be not to bring other
affected children to the physician at the clinics
or hospitals, causing thus an additional ascer-
tainment bias to the hospital-based studies
(Vogel and Motulsky 1997).
MEANING OF THE RESULTS 
AND PERSPECTIVES
A modern approach to the dys-
trophinopathies in a developing country with
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health profile of a developed nation opened
more questions than it pretended to answer.
Despite the expertise of the pediatrician per-
forming the differential diagnostics at the
HNN and the installed technical capacity for
molecular genetic analyses at the UCR, the
study showed a fragmentary panorama of the
epidemiology of these diseases: the geograph-
ic distribution of the detected cases, the small
percentage of patients with deletions and the
high number of de novo mutations point to a
significant ascertainment bias mainly caused
by lack of report and reference of patients to
the HNN. This surely is a problem affecting
other genetic studies in the country, a problem
that could impair the further improvement of
the Costa Rican health profiles. To attain such
purpose, efforts must be also directed to the
prevention and adequate treatment of chronic
diseases, which undoubtedly have an impor-
tant genetic basis. If the descriptive genetic
epidemiology cannot be accurately determined
the health system cannot be prepared in
advance to confront the challenge.
Useful data for these studies begin with
correct phenotyping, i.e. right diagnosis. This
is a matter of physicians. How long will it take
to have them prepared and aware of the impor-
tance of their role in this task will not only
depend on medical schools but also on politi-
cal commitment by the Health Ministerium
and the CCSS authorities and of physicians
themselves, a difficult enterprise, however fea-
sible. In the meantime, advances in the molec-
ular basis of genetic disease and its diagnosis
will only have a minor impact on public health
and on the development of significant research
in Costa Rica.
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RESUMEN
Un estudio de cinco años tendiente a describir la epi-
demiología genética básica de las distrofinopatías en Costa
Rica detectó 31 pacientes con sintomatología de DMD o
de BMD en el Hospital Nacional de Niños (HNN), el cen-
tro de referencia del sistema nacional de salud para ene-
frmedades hereditarias, sin embargo, la distribución
geográfica de los pacientes, un bajo porcentaje de dele-
ciones y una muy elevada proporción de mutaciones de
novo indican que un significante sesgo de averiguación
impide el estudio científico de riguroso tendiente a dis-
minuir el impacto de estas enfermedades en Costa Rica.
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